SCHEMBL5440744

SCHEMBL5440744

NC(=O)C1CCN(c2ccc3c(=O)c4c(O)cc(N5CCOCC5)cc4oc3c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.52
ALDH1A1 P00352 1/20 0.52
PRKDC P78527 8/20 0.46
PKM P14618 1/20 0.41
PIK3CD O00329 2/20 0.40
PIK3CA P42336 2/20 0.40
PIK3CB P42338 2/20 0.40
PIK3CG P48736 2/20 0.40
SLC16A3 O15427 1/20 0.40
LGMN Q99538 1/20 0.39
BRCA1 P38398 1/20 0.39
TBK1 Q9UHD2 1/20 0.38
MGAM O43451 1/20 0.38
GAA P10253 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
SYK P43405 1/20 0.37
MMP1 P03956 1/20 0.37
PTPN1 P18031 1/20 0.37
MAOA P21397 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5783171 0.91 PRKDC (0.49) MAPTALDH1A1PRKDCPKMPIK3CD
SCHEMBL14802145 0.91 PRKDC (0.47) MAPTALDH1A1PRKDCPKMPIK3CD
SCHEMBL5441394 0.82 PRKDC (0.50) MAPTPRKDCPKMPIK3CDPIK3CA
SCHEMBL5440694 0.82 PRKDC (0.55) MAPTALDH1A1PRKDCMGAMGAA
SCHEMBL5781920 0.81 PRKDC (0.53) MAPTPRKDCPKMPIK3CDPIK3CA
SCHEMBL5453418 0.80 PRKDC (0.52) MAPTPRKDCPKMPIK3CDPIK3CA
SCHEMBL14802143 0.80 PRKDC (0.52) MAPTPRKDCPKMPIK3CDPIK3CA
SCHEMBL5454434 0.78 MGAM (0.63) ALDH1A1PRKDCMGAMGAASI
SCHEMBL5444190 0.77 PRKDC (0.56) MAPTPRKDCMGAMGAAMAOA
SCHEMBL5782473 0.77 PRKDC (0.49) MAPTALDH1A1PRKDCPKMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167441-A1 Xanthones, thioxanthones and acridinones as dna-pk inhibitors LUITPOLD PHARMACEUTICALS, INC. 2007-07-19 US claimed
US-8404681-B2 Xanthones, thioxanthones and acridinones as DNA-PK inhibitors LUITPOLD PHARMACEUTICALS, INC. (US) 2013-03-26 US disclosed
US-8404681-B2 Xanthones, thioxanthones and acridinones as DNA-PK inhibitors LUITPOLD PHARMACEUTICALS, INC. (US) 2013-03-26 US disclosed
US-8404681-B2 Xanthones, thioxanthones and acridinones as DNA-PK inhibitors LUITPOLD PHARMACEUTICALS, INC. (US) 2013-03-26 US disclosed
US-20070167441-A1 Xanthones, thioxanthones and acridinones as dna-pk inhibitors LUITPOLD PHARMACEUTICALS, INC. 2007-07-19 US disclosed
US-20070167441-A1 Xanthones, thioxanthones and acridinones as dna-pk inhibitors LUITPOLD PHARMACEUTICALS, INC. 2007-07-19 US disclosed
US-20070167441-A1 Xanthones, thioxanthones and acridinones as dna-pk inhibitors LUITPOLD PHARMACEUTICALS, INC. 2007-07-19 US disclosed
EP-1660473-A2 XANTHONES, THIOXANTHONES AND ACRIDINONES AS DNA-PK INHIBITORS Luitpold Pharmaceuticals, Inc. (US) 2006-05-31 EP disclosed
WO-2004085418-A2 XANTHONES, THIOXANTHONES AND ACRIDINONES AS DNA-PK INHIBITORS LUITPOLD PHARMACEUTICALS, INC. (US) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167441-A1 Xanthones, thioxanthones and acridinones as dna-pk inhibitors DCK, DTYMK, XPA MAPT 3597/4885ALDH1A1 3664/4885PRKDC 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.